OnKure Therapeutics, Inc.(OKUR)

$3.79—Stale · unknown old

Chart

OnKure Therapeutics, Inc.(OKUR)

NASDAQ • Last print unknown ago

$3.79—Stale · unknown old

Chart Studio

OKUR(OKUR)

OKUR

Overview Fair Value Stream Notebook Intel Chart History Fundamentals TTM Earnings Analysts News Financials Insiders Institl.DCF Peers

Q4 2026 EPS Estimate

$-0.36

Nov 5, 2026

Revenue Estimate

$166,667

Analyst Sentiment

Wall St. Consensus

Buy

2 analysts·Low coverage

Score

2 Buy (100%)0 Hold (0%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

2100%

Hold

00%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$14.00

+269.4%

Consensus

$14.00

+269.4%

Bull

$14.00

+269.4%

12-Month Target Range2 analysts

$14.00$14.00$14.00

Current $3.79Consensus

Current Price

$3.79

Upside to Consensus

$10.21

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+100.00%

EPS—

FY2028

Rev+200.00%

EPS—

FY2029

Rev+0.00%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$333,333	$666,667	$2M	$2M	$2M
Low	$333,333	$666,667	$2M	$2M	$2M
High	$333,333	$666,667	$2M	$2M	$2M
EBITDA Avg	$-24M	$-20M	$-18M	$-15M	$-17M
Low	$-27M	$-20M	$-25M	$-15M	$-17M
High	$-20M	$-20M	$-11M	$-15M	$-17M
EBIT Avg	$-25M	$-21M	$-18M	$-16M	$-17M
Low	$-28M	$-21M	$-25M	$-16M	$-17M
High	$-21M	$-21M	$-11M	$-16M	$-17M
Net Income Avg	$-25M	$-21M	$-18M	$-16M	$-17M
Low	$-28M	$-21M	$-25M	$-16M	$-17M
High	$-21M	$-21M	$-11M	$-16M	$-17M
EPS Avg	$-1.83	$-1.53	$-1.32	$-1.17	$-1.26
Low	$-2.08	$-1.53	$-1.86	$-1.17	$-1.26
High	$-1.57	$-1.53	$-0.85	$-1.17	$-1.26
Analysts (Rev / EPS)	3 / 3	2 / 2	3 / 3	1 / 1	2 / 1

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$166,667	$166,667	$500,000	$500,000	$500,000	$500,000
Low	$166,667	$166,667	$500,000	$500,000	$500,000	$500,000
High	$166,667	$166,667	$500,000	$500,000	$500,000	$500,000
EBITDA Avg	$-20M	$-22M	$-15M	$-16M	$-14M	$-12M
Low	$-24M	$-26M	$-15M	$-16M	$-14M	$-12M
High	$-16M	$-17M	$-15M	$-16M	$-14M	$-12M
EBIT Avg	$-20M	$-22M	$-15M	$-16M	$-14M	$-12M
Low	$-24M	$-26M	$-15M	$-16M	$-14M	$-12M
High	$-16M	$-18M	$-15M	$-16M	$-14M	$-12M
Net Income Avg	$-20M	$-22M	$-15M	$-16M	$-14M	$-12M
Low	$-24M	$-26M	$-15M	$-16M	$-14M	$-12M
High	$-16M	$-18M	$-15M	$-16M	$-14M	$-12M
EPS Avg	$-0.41	$-0.43	$-0.31	$-0.32	$-0.28	$-0.25
Low	$-0.48	$-0.52	$-0.31	$-0.32	$-0.28	$-0.25
High	$-0.33	$-0.35	$-0.31	$-0.32	$-0.28	$-0.25
Analysts (Rev / EPS)	2 / 3	2 / 3	1 / 1	1 / 1	1 / 1	1 / 1

Earnings Surprises

Recent Analyst Actions

Aug 14, 2026Oppenheimer

OnKure Therapeutics price target lowered to $14 from $30 at Oppenheimer

Target:$14.00

+256.9%from $3.92

Oct 10, 2024Oppenheimer

OnKure Therapeutics initiated with an Outperform at Oppenheimer

Target:$35.00

+89.2%from $18.50

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance